CRISPR Therapeutics AG (CRSP) Short-term Investments (2020 - 2026)

CRISPR Therapeutics AG has disclosed Short-term Investments across 7 years of filings, most recently posting $2.0 billion for Q1 2026.

• Short-term Investments for Q1 2026 came in at $2.0 billion, up 24.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 24.59% YoY), and the FY2025 annual result was $1.6 billion, up 1.41% from the prior year.
• Short-term Investments came in at $2.0 billion for Q1 2026 at CRISPR Therapeutics AG, up from $1.6 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $2.0 billion in Q1 2026 to a low of $1.2 billion in Q3 2023.
• The 5-year median for Short-term Investments is $1.5 billion (2023), against an average of $1.5 billion.
• Across the five-year window, Short-term Investments surged 126.03% in 2022 and slipped 18.66% in 2023, its largest moves.
• CRISPR Therapeutics AG's Short-term Investments stood at $1.6 billion in 2022, then dropped by 18.66% to $1.3 billion in 2023, then grew by 23.11% to $1.6 billion in 2024, then rose by 1.41% to $1.6 billion in 2025, then gained by 23.96% to $2.0 billion in 2026.
• The last three Short-term Investments figures came in at $2.0 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.